Off target effects of HIV integrase strand transfer inhibitors in cell and animal models: a scoping review.

Abstract

In the past decade, integrase strand transfer inhibitor (INSTI)-containing regimens have become the most widely used HIV treatment worldwide. Despite their high efficacy and tolerability, numerous adverse effects have been reported, including weight gain, neuropsychiatric effects, and reproductive health concerns. These reports were the impetus for an array of postapproval in vitro and in vivo studies. This scoping review consolidates and discusses all research conducted post-INSTI approval, from 2007 to 2024, that focused on the effects of INSTI exposure in cell and animal models. It provides insights into potential effects and mechanistic details that may not be revealed through clinical trials.